Stock listing
NASDAQ:CADL Candel Therapeutics, Inc. Stock
Home listing (NASDAQ) of Candel Therapeutics, Inc.
Follow Candel Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:CADL
$5.04 USD -0.28 (-5.3%)
Close on Nov 20, 2026
- Day range
- $4.90 – $5.31 USDNov 20, 2026
- Volume
- 1.72M sharesNov 20, 2026
- Market cap
- $395.4M USDAt the close on Nov 20, 2026 · price × 78.45M shares outstanding
- 52-week range
- $4.35 – $14.00 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $12.16M USDMedian day 989,443 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:CADL · Home | $5.04 USD | -0.28 (-5.3%) | 1,723,500 | $5.00 | $5.31 | $4.90 | $5.32 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CADL · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $5.04 | -0.28 | -5.3% | $5.00 | $5.31 | $4.90 | 1,723,500 | |
| $5.32 | -0.08 | -1.5% | $5.35 | $5.637 | $5.26 | 1,389,374 | |
| $5.40 | -0.41 | -7.1% | $5.78 | $6.04 | $5.33 | 1,803,756 | |
| $5.81 | -0.39 | -6.3% | $5.94 | $6.23 | $5.725 | 3,269,772 | |
| $6.20 | -2.19 | -26.1% | $5.325 | $6.63 | $5.20 | 6,622,128 | |
| $8.39 | -0.83 | -9.0% | $9.11 | $9.21 | $8.335 | 1,935,346 | |
| $9.22 | -0.13 | -1.4% | $9.53 | $9.54 | $9.18 | 1,096,934 | |
| $9.35 | -0.14 | -1.5% | $9.40 | $9.65 | $9.089 | 623,545 | |
| $9.49 | +0.74 | +8.5% | $8.99 | $9.84 | $8.65 | 1,371,305 | |
| $8.75 | +0.71 | +8.8% | $8.24 | $8.75 | $8.06 | 955,020 | |
| $8.04 | -1.01 | -11.2% | $8.98 | $9.009 | $7.92 | 1,228,485 | |
| $9.05 | +0.23 | +2.6% | $8.93 | $9.33 | $8.71 | 993,819 | |
| $8.82 | +0.70 | +8.6% | $8.19 | $8.86 | $8.19 | 3,304,421 | |
| $8.12 | -0.21 | -2.5% | $8.35 | $8.61 | $8.011 | 862,017 | |
| $8.33 | -0.32 | -3.7% | $8.56 | $8.61 | $8.16 | 779,925 | |
| $8.65 | -0.02 | -0.2% | $8.72 | $8.93 | $8.553 | 740,959 | |
| $8.67 | +0.42 | +5.1% | $8.13 | $8.69 | $8.13 | 663,859 | |
| $8.25 | +0.46 | +5.9% | $7.78 | $8.37 | $7.741 | 928,461 | |
| $7.79 | -0.24 | -3.0% | $8.44 | $8.44 | $7.70 | 849,302 | |
| $8.03 | -0.35 | -4.2% | $8.33 | $8.33 | $7.905 | 1,184,816 | |
| $8.38 | +0.01 | +0.1% | $8.45 | $8.79 | $8.255 | 762,579 | |
| $8.37 | -0.27 | -3.1% | $8.65 | $8.82 | $8.35 | 1,102,647 | |
| $8.64 | +0.43 | +5.2% | $8.17 | $8.84 | $8.125 | 1,126,151 | |
| $8.21 | +0.02 | +0.2% | $8.37 | $8.499 | $7.96 | 1,278,696 | |
| $8.19 | -0.72 | -8.1% | $8.92 | $8.92 | $8.125 | 1,513,092 | |
| $8.91 | -0.16 | -1.8% | $9.01 | $9.10 | $8.79 | 989,338 | |
| $9.07 | -0.20 | -2.2% | $9.06 | $9.43 | $9.03 | 989,443 | |
| $9.27 | -0.51 | -5.2% | $9.78 | $9.845 | $9.22 | 1,133,162 | |
| $9.78 | -0.16 | -1.6% | $10.00 | $10.18 | $9.71 | 744,631 | |
| $9.94 | +0.28 | +2.9% | $9.69 | $9.95 | $9.59 | 718,368 | |
| $9.66 | -0.16 | -1.6% | $9.70 | $9.755 | $9.45 | 888,496 | |
| $9.82 | -0.05 | -0.5% | $9.75 | $9.945 | $9.60 | 714,954 | |
| $9.87 | -0.36 | -3.5% | $10.32 | $10.40 | $9.85 | 977,769 | |
| $10.23 | +0.05 | +0.5% | $10.27 | $10.45 | $9.94 | 980,886 | |
| $10.18 | +0.02 | +0.2% | $10.29 | $10.37 | $10.03 | 878,803 | |
| $10.16 | -0.28 | -2.7% | $10.72 | $10.72 | $10.16 | 1,037,610 | |
| $10.44 | -0.44 | -4.0% | $11.02 | $11.25 | $10.37 | 1,268,853 | |
| $10.88 | -0.31 | -2.8% | $11.25 | $11.25 | $10.57 | 963,288 | |
| $11.19 | +0.17 | +1.5% | $10.98 | $11.52 | $10.76 | 771,016 | |
| $11.02 | -0.53 | -4.6% | $11.50 | $11.55 | $11.01 | 799,764 | |
| $11.55 | +0.26 | +2.3% | $11.22 | $11.59 | $10.85 | 883,107 | |
| $11.29 | -0.56 | -4.7% | $11.93 | $12.01 | $11.27 | 1,287,820 | |
| $11.85 | +0.64 | +5.7% | $11.28 | $11.96 | $11.15 | 882,043 | |
| $11.21 | +0.36 | +3.3% | $11.85 | $11.90 | $11.13 | 1,086,919 | |
| $10.85 | -0.49 | -4.3% | $11.28 | $11.38 | $10.78 | 3,014,534 | |
| $11.34 | +0.32 | +2.9% | $10.95 | $11.50 | $10.86 | 798,618 | |
| $11.02 | -0.10 | -0.9% | $11.16 | $11.43 | $10.83 | 1,168,698 | |
| $11.12 | +0.445 | +4.2% | $10.63 | $11.14 | $10.41 | 1,065,387 | |
| $10.68 | +0.13 | +1.2% | $10.41 | $10.97 | $10.32 | 940,804 | |
| $10.55 | -0.785 | -6.9% | $11.32 | $11.41 | $9.855 | 3,596,201 | |
| $11.33 | -0.84 | -6.9% | $12.05 | $12.05 | $11.20 | 1,952,924 | |
| $12.17 | -0.43 | -3.4% | $12.52 | $12.78 | $12.13 | 661,253 | |
| $12.60 | -0.18 | -1.4% | $12.57 | $12.85 | $12.02 | 1,002,103 | |
| $12.78 | -0.19 | -1.5% | $12.91 | $13.05 | $12.76 | 535,822 | |
| $12.97 | -0.23 | -1.7% | $13.21 | $13.28 | $12.73 | 628,312 | |
| $13.20 | +0.35 | +2.7% | $12.81 | $13.41 | $12.67 | 807,852 | |
| $12.85 | -0.22 | -1.7% | $12.93 | $13.04 | $12.60 | 935,641 | |
| $13.07 | 0.00 | 0.0% | $13.02 | $13.22 | $12.63 | 895,013 | |
| $13.07 | -0.68 | -4.9% | $13.64 | $13.80 | $12.88 | 1,236,463 | |
| $13.75 | +0.47 | +3.5% | $13.26 | $14.00 | $13.20 | 1,185,355 | |
| $13.28 | -0.32 | -2.4% | $13.60 | $13.85 | $13.19 | 977,998 | |
| $13.60 | +0.74 | +5.8% | $13.09 | $13.95 | $12.97 | 1,342,938 | |
| $12.86 | -0.27 | -2.1% | $12.99 | $12.99 | $12.40 | 959,088 | |
| $13.13 | +0.78 | +6.3% | $12.52 | $13.26 | $12.38 | 1,339,298 | |
| $12.35 | -1.15 | -8.5% | $13.23 | $13.38 | $12.33 | 1,541,934 |
- Ticker
- NASDAQ:CADL
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
Candel Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 73 slides
Latest news
Candel Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
Nov 12, 2026
Closed $6.20 (-26.1%) on Nov 13, 2026
Candel Therapeutics Presents SITC 2026 Data Highlighting Systemic Immune Activation and Survival Outcomes Across Clinical-Stage Portfolio
Nov 6, 2026
Closed $8.75 (+8.8%) on Nov 6, 2026
Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Nov 5, 2026
Closed $8.75 (+8.8%) on Nov 6, 2026
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 2, 2026
Closed $8.82 (+8.6%) on Nov 3, 2026
Candel Therapeutics Announces Late-Breaking Abstract Accepted for Poster Presentation at the SITC 2026 Annual Meeting, Featuring Aglatimagene Besadenovec Data in Localized Prostate Cancer
Oct 29, 2026
Closed $8.65 (-0.2%) on Oct 29, 2026
Candel Therapeutics to Present at November Investor Conferences
Oct 27, 2026
Closed $8.25 (+5.9%) on Oct 27, 2026
Candel Therapeutics Appoints Maria Ostrovsky as General Counsel
Oct 22, 2026
Closed $8.38 (+0.1%) on Oct 22, 2026
Candel Therapeutics to Present at the SITC 2026 Annual Meeting
Oct 2, 2026
Closed $10.18 (+0.2%) on Oct 2, 2026
Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI
Oct 1, 2026
Closed $10.16 (-2.7%) on Oct 1, 2026
Candel Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 36 in the last 12 months · 133 in all · newest Nov 12, 2026 · oldest 2021
- Decks
- 14 decks · latest September 2026
Where Candel Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:CADL · Home listing · This page | NASDAQ | United States | USD |
| BOATS:CADL | BOATS | United States | USD |
Valuation
Price/book 3.0× against a median of 4.2×: 5th lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $193.8M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 3.0×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 2.03
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Candel Therapeutics, Inc. · NASDAQ:CADL | US$395.4M | US$193.8M | n/a | n/a | n/a | 3.0× | n/a | 0.0× | 2.03 |
| Jacobio Pharmaceuticals Group Co., Ltd. · HKEX:1167 | US$401.1M | US$173.5M | n/a | 22.2× | n/a | 2.0× | −272.7% | 0.1× | n/a |
| Ever Supreme Bio Technology Co., Ltd. · TPEX:6712 | US$394.8M | US$362.8M | 27.5× | 11.1× | 23.9× | 4.6× | 43.8% | 0.0× | n/a |
| Mezzion Pharma Co., Ltd. · KRX:140410 | US$391.0M | US$360.8M | n/a | 57.3× | n/a | 13.4× | −325.0% | 0.0× | n/a |
| Avalo Therapeutics, Inc. · NASDAQ:AVTX | US$390.9M | −US$1.93M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 1.25 |
| Qurient Co., Ltd. · KRX:115180 | US$388.5M | US$372.4M | n/a | 70.5× | n/a | 30.2× | −543.0% | 0.8× | n/a |
| Beijing Luzhu Biotechnology Co., Ltd. Class H · HKEX:2480 | US$388.2M | US$369.1M | n/a | n/a | n/a | 4.3× | n/a | 0.4× | n/a |
| Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H · HKEX:3378 | US$387.5M | US$316.0M | n/a | n/a | n/a | 4.1× | n/a | 0.1× | n/a |
| Opus Genetics, Inc. · NASDAQ:IRD | US$385.7M | US$332.3M | n/a | 42.0× | n/a | 10.0× | n/a | 0.9× | 1.01 |
| Eupraxia Pharmaceuticals, Inc. · TSX:EPRX | US$384.3M | US$252.7M | n/a | n/a | n/a | 2.9× | n/a | 0.0× | 1.53 |
| Hinova Pharmaceuticals, Inc. Class A · SSE:688302 | US$381.1M | US$285.9M | n/a | 23.0× | n/a | 2.6× | −167.3% | 0.1× | n/a |
| Median of the others | US$388.4M | US$324.2M | 27.5× | 32.5× | 23.9× | 4.2× | −272.7% | 0.1× | 1.25 |
Forecasts
10 strong buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 19.11 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.08 · 3 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Paul Peter Tak | President & Chief Executive Officer |
| Charles Schoch | Chief Financial Officer |
| Edward J. Benz | President |
| Gary Nabel | President |
| Maria Ostrovsky | General Counsel |
| Theodore Jenkins | Vice President |
| Francesca Barone | Chief Scientific Officer |
| Henry Brem | Director, Department of Neurosurgery |
| James P. Allison | Chief of the Department of Immunology |
| Mark Sims | Chief Commercial Officer |
| Philip Kantoff | Co-Founder, Convergent Therapeutics |
| Roy Herbst | Director, Dartmouth Cancer Center |
| Seshu Tyagarajan | Chief Technical and Development Officer |
| Susan Stewart | Chief Regulatory Officer |
| W. Garrett Nichols | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Joseph Papa | Chairman |
| Paul B. Manning | Chair of the Board |
| Elizabeth Jaffee | Deputy Director |
| Martine Zimmermann | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · After close | −26.1% |
| Q2 2026 | Aug 13, 2026 · Before open | +10.5% |
| Q1 2026 | May 14, 2026 · Before open | −0.3% |
| Q4 2025 | Mar 26, 2026 | −3.6% |
| Q3 2025 | Nov 13, 2025 · Before open | −6.3% |
| Q2 2025 | Aug 14, 2025 · Before open | −5.6% |
| Q1 2025 | May 13, 2025 · Before open | +7.7% |
| Q4 2024 | Mar 13, 2025 | +8.2% |
| Q3 2024 | Nov 14, 2024 | −11.4% |
| Q2 2024 | Aug 13, 2024 | −5.7% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 14, 2024 · Before open | +4.9% |
| Q4 2023 | Mar 28, 2024 · Before open | +2.6% |
| Q3 2023 | Nov 9, 2023 · Before open | −13.0% |
| Q2 2023 | Aug 10, 2023 · Before open | −3.6% |
| Q1 2023 | May 11, 2023 · Before open | −3.4% |
| Q4 2022 | Mar 30, 2023 · Before open | −2.0% |
| Q3 2022 | Nov 10, 2022 · Before open | +10.7% |
| Q2 2022 | Aug 5, 2022 · Before open | +1.4% |
| Q1 2022 | May 12, 2022 · Before open | +3.5% |
| Q4 2021 | Mar 29, 2022 · Before open | −2.6% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 73 slides | September 2026 |
| Corporate Update (May 2026) | Corporate update | 23 slides | May 15, 2026 |
| AUA 2026 | Conference | 17 slides | May 2026 |
| Investor Day (December 2025) | Investor day | 80 slides | Dec 5, 2025 |
| ASTRO 2025 | Conference | 19 slides | September 2025 |
| ASCO 2025 | Conference | 18 slides | May 27, 2025 |
| Investor Presentation (March 2025) | Investor deck | 47 slides | Mar 27, 2025 |
| Technical Presentation (December 2024) | Technical | 41 slides | Dec 11, 2024 |
| Rotterdam IOVC 2024 | Conference | 32 slides | Oct 28, 2024 |
| Technical Presentation (January 2024) | Technical | 46 slides | Jan 17, 2024 |
All 14 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (May 2023) | Technical | 23 slides | May 19, 2023 |
| ASGCT 2023 | Conference | 23 slides | May 2023 |
| Investor Day (December 2022) | Investor day | 107 slides | Dec 6, 2022 |
| Breakfast Event during ASCO 2022 Annual Meeting | Conference | 46 slides | Jun 6, 2022 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Announced: US$100M · US$5.45 a share · Citigroup +5 Dealers: LifeSci Capital (lead), Citigroup (co-lead), Cantor (co-lead), Stifel (co-lead), H.C. Wainwright & Co., Brookline Capital Markets Use of proceeds: Launch readiness and commercial activities for aglatimagene in prostate cancer, phase 3 NSCLC trial costs, and general corporate purposes | Feb 20, 2026 |
| Registered direct offering of common stock Announced: about US$15M · US$4.67 a share Insiders: Investors include executive officers and members of the Company's Board of Directors. Use of proceeds: Launch readiness, medical affairs and pre-commercialization for CAN-2409 in prostate cancer ahead of a BLA submission, and general corporate purposes | Jun 24, 2025 |
| Public offering of common stock and pre-funded warrants Closed: US$92M raised · US$6 a share · Citigroup +3 Dealers: Citigroup (co-lead), BofA Securities (co-lead), Canaccord Genuity (co-lead), H.C. Wainwright & Co. Use of proceeds: Continue development of product candidates, including preparing a BLA submission for CAN-2409 in prostate cancer, and general corporate purposes | Dec 16, 2024 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$8.00 a share on Jul 26, 2021.
- Price
- US$8.00 a share
- Shares offered
- 9,000,000 shares of common stock
- Offering size
- US$72 million
- Underwriters' option
- Up to 1,350,000 more shares
- Underwriters
- Jefferies, Credit Suisse, BMO Capital Markets, UBS Investment Bank · In the order on the cover
- Shares delivered
- On or about Jul 29, 2021
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Feb 16, 2021 |
| Filed publicly | Jun 25, 2021 |
| Amended 3 times | Newest Jul 26, 2021 |
| Shares registered with an exchange | Jul 19, 2021 |
| Declared effective by the SEC | Jul 26, 2021 |
| Final prospectus, with the price | Jul 28, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jul 28, 2021 |
| EFFECT · Notice that a registration is effective | Jul 26, 2021 |
| CORRESP · Letter to the SEC | Jul 26, 2021 |
| CORRESP · Letter to the SEC | Jul 26, 2021 |
| S-1/A · Registration statement, amended | Jul 26, 2021 |
| CERT · Exchange's certificate of listing | Jul 22, 2021 |
| S-1/A · Registration statement, amended | Jul 21, 2021 |
| CORRESP · Letter to the SEC | Jul 20, 2021 |
| CORRESP · Letter to the SEC | Jul 20, 2021 |
| CORRESP · Letter to the SEC | Jul 20, 2021 |
All 22 filings
| Filing | Filed |
|---|---|
| UPLOAD · Letter from the SEC | Jul 19, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Jul 19, 2021 |
| CORRESP · Letter to the SEC | Jul 16, 2021 |
| S-1/A · Registration statement, amended | Jul 16, 2021 |
| UPLOAD · Letter from the SEC | Jul 12, 2021 |
| CORRESP · Letter to the SEC | Jul 7, 2021 |
| S-1 · Registration statement | Jun 25, 2021 |
| UPLOAD · Letter from the SEC | Apr 9, 2021 |
| DRS/A · Draft registration statement, amended | Mar 31, 2021 |
| DRSLTR · Letter to the SEC with a draft | Mar 30, 2021 |
| UPLOAD · Letter from the SEC | Mar 15, 2021 |
| DRS · Draft registration statement | Feb 16, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed Jul 28, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 31.0K | 125.0K | 125.0K | 125.0K | 125.0K |
| Cost of revenue | 845.0K | 990.0K | 24.0M | 987.0K | 232.0K | 6.61M | |
| Gross profit | -845.0K | -990.0K | -24.0M | 125.0K | 125.0K | 125.0K | 125.0K |
| Research and development | 30.5M | 19.3M | 24.5M | 20.8M | 15.2M | 8.75M | 6.61M |
| Selling, general and administrative | 17.8M | 14.1M | 13.9M | 14.1M | 10.7M | 5.18M | 2.56M |
| Operating income | -48.3M | -33.4M | -38.4M | -34.7M | -25.7M | -13.8M | -9.04M |
| Depreciation and amortization | 845.0K | 990.0K | 960.0K | 778.0K | 232.0K | 91.0K | 43.0K |
| EBITDA | -47.4M | -32.4M | -37.4M | -33.9M | -25.5M | -13.7M | -8.99M |
| Interest expense | 2.12M | 2.09M | -2.60M | 1.71M | 53.0K | 111.0K | 1.07M |
| Income before tax | -38.2M | -55.2M | -37.9M | -18.8M | -36.1M | -17.7M | -8.24M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 4.49M | -226.0K |
| Net income | -38.2M | -55.2M | -37.9M | -18.8M | -36.1M | -17.7M | -8.24M |
| Earnings per share, basic | -0.72 | -1.74 | -1.31 | -0.65 | -1.91 | -1.52 | -0.44 |
| Earnings per share, diluted | -0.72 | -1.74 | -1.31 | -0.65 | -1.91 | -1.52 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 119.7M | 102.7M | 35.4M | 70.1M | 82.6M | 35.1M | 5.18M |
| Short-term investments | 0 | 39.9M | |||||
| Current assets | 121.4M | 103.8M | 36.8M | 71.9M | 84.9M | 35.1M | 45.2M |
| Property, plant and equipment | 1.64M | 2.19M | 3.21M | 4.42M | 3.84M | 2.79M | 425.0K |
| Total assets | 125.2M | 106.9M | 41.2M | 77.7M | 89.2M | 38.3M | 45.9M |
| Accounts payable | 1.13M | 237.0K | 422.0K | 380.0K | 1.59M | 921.0K | 218.0K |
| Current liabilities | 9.00M | 37.5M | 14.2M | 5.62M | 5.36M | 4.71M | 1.41M |
| Long-term debt | 47.1M | 1.73M | 11.6M | 20.9M | 560.0K | 483.0K | 420.0K |
| Total debt | 0 | 11.6M | 20.5M | 22.8M | 560.0K | 483.0K | 420.0K |
| Total liabilities | 73.3M | 40.5M | 28.5M | 30.0M | 25.1M | 12.8M | 53.9M |
| Shareholders' equity | 51.9M | 66.3M | 12.7M | 47.7M | 64.1M | -23.6M | -8.04M |
| Shares outstanding | 54.9M | 46.8M | 29.1M | 28.9M | 28.7M | 11.6M | 18.7M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -38.3M | -27.0M | -34.2M | -31.4M | -22.2M | -9.07M | -5.18M |
| Capital spending | -587.0K | -16.0K | -457.0K | -1.30M | -1.83M | -1.48M | -159.0K |
| Free cash flow | -38.9M | -27.0M | -34.7M | -32.7M | -24.1M | -10.5M | -5.34M |
| Cash from investing | -560.0K | -16.0K | -280.0K | -1.30M | -1.83M | 38.5M | -35.7M |
| Cash from financing | 56.1M | 94.3M | -121.0K | 20.0M | 71.8M | 490.0K | 22.0M |
| Share buybacks | -121.0K | 71.8M | |||||
| Change in cash | 17.2M | 67.2M | -34.6M | -12.7M | 47.7M | 29.9M | -18.9M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 12, 2026 | Current report | SEC |
| 424B5 · Prospectus | Nov 12, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| 4 · Change in ownership | Nov 5, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Sep 11, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 10, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 10, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 10, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 10, 2026 | Management or board change | SEC |
| 8-K · Current report | Sep 9, 2026 | Current report | SEC |
| 4 · Change in ownership | Aug 19, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 17, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 27, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 8, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 29, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 29, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 24, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Jun 16, 2026 | Management or board change | SEC |
| 8-K · Current report | May 15, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 29, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2026 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 27, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 18, 2026 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Mar 12, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 12, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 12, 2026 | Results | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 23, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Feb 20, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Feb 19, 2026 | Offer document | SEC |
| 8-K · Current report | Feb 19, 2026 | Results | SEC |
| 4 · Change in ownership | Jan 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 21, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Dec 5, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Nov 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2025 | Results | SEC |
| 8-K · Current report | Oct 14, 2025 | Results | SEC |
| EFFECT · Notice that a registration is effective | Aug 25, 2025 | Other filings | SEC |
| 8-K · Current report | Aug 21, 2025 | Material contract | SEC |
| CORRESP · Letter to the SEC | Aug 20, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 20, 2025 | Other filings | SEC |
| S-3 · Registration statement | Aug 14, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2025 | Results | SEC |
| 4 · Change in ownership | Jul 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 30, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 30, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 24, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Jun 24, 2025 | Offer document | SEC |
| 8-K · Current report | Jun 23, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 18, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 6, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 6, 2025 | Management or board change | SEC |
| 8-K · Current report | May 28, 2025 | Current report | SEC |
| 8-K · Current report | May 22, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 29, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 23, 2025 | Current report | SEC |
| 8-K · Current report | Mar 26, 2025 | Current report | SEC |
| 4 · Change in ownership | Mar 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 20, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Mar 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 19, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 18, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 18, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 18, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 17, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 17, 2025 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Mar 13, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 13, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 13, 2025 | Results | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 25, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 14, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 13, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 7, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 7, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 7, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 15, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 15, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 15, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 15, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 15, 2025 | Other filings | SEC |
| 8-K · Current report | Jan 13, 2025 | Results | SEC |
| 4 · Change in ownership | Jan 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 10, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 8, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 8, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 8, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 8, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 8, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Dec 17, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 13, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 13, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Dec 13, 2024 | Offer document | SEC |
| 424B5 · Prospectus | Dec 12, 2024 | Offer document | SEC |
| 8-K · Current report | Dec 11, 2024 | Current report | SEC |
| 4 · Change in ownership | Dec 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 3, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 29, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 29, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 29, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 29, 2024 | Other filings | SEC |
| 4 · Change in ownership | Nov 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2024 | Results | SEC |
| 4 · Change in ownership | Nov 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 28, 2024 | Insider trade | SEC |
| 8-K · Current report | Oct 28, 2024 | Current report | SEC |
| 4 · Change in ownership | Oct 15, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 23, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 13, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2024 | Results | SEC |
| 4 · Change in ownership | Jul 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 19, 2024 | Insider trade | SEC |
This page holds 200 of 423 filings. Open Filings
Cap table
Built by 6ix from Candel Therapeutics, Inc.’s releases · as of Nov 5, 2026
- Common shares
- 78,445,937
- Fully diluted
- 78,445,937
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 78,445,937 | Nov 5, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 5, 2026 | 78,445,937 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Jason Amello Other companies: TScan Therapeutics, Inc. (Chief Financial Officer · Since at least Jan 29, 2024); Acer Therapeutics Inc (Director · Jan 2, 2020 – Mar 14, 2023 · Past); Akebia Therapeutics, Inc. (SVP, CFO & Treasurer · Apr 11, 2019 – Feb 28, 2020 · Past) | Chief Financial Officer · Sep 21, 2022 – Nov 28, 2023 · Past |
| Diem Nguyen Other companies: SIGA Technologies Inc. (Chief Executive Officer, Director · Since at least Jan 27, 2024); Verrica Pharmaceuticals Inc. (Director · Since at least Jun 9, 2020) | Director · Since at least Jul 26, 2021 |
| Gary J. Nabel Other companies: OPKO Health, Inc. (President and CEO of ModeX Therapeutics, Chief Innovation Officer · Since at least May 12, 2026); SIGA Technologies Inc. (Board Member · Jun 10, 2026 – Nov 10, 2026 · Past) | President · Since at least Nov 5, 2026 |
| Maha Radhakrishnan Other companies: Entrada Therapeutics, Inc. (Industry Leader and Independent Director · Since at least Jun 1, 2025); Alto Neuroscience, Inc. (Director · Mar 8, 2024 – Mar 8, 2024 · Past) | Director · Since at least Jun 4, 2025 |
| Edward J Benz Jr Other companies: Deciphera Pharmaceuticals LLC (Director · Jun 11, 2024 – Jun 11, 2024 · Past) | Director · Since at least Jun 26, 2024 |
| Paul B. Manning Other companies: Verrica Pharmaceuticals Inc. (Chairman · Since at least Oct 22, 2026) | Chair of the Board · Since at least Sep 10, 2026 |
| W. Garrett Nichols Other companies: Chimerix Inc (Chief Medical Officer · Sep 2, 2014 – Feb 7, 2020 · Past) | Chief Medical Officer · Since at least Sep 12, 2022 |
| Charles Schoch | Chief Financial Officer · Since at least Oct 14, 2025 |
| Christopher Martell | Director · Since at least Jul 26, 2021 |
| Edward J. Benz | President · Since at least Nov 5, 2026 |
All 25 people
| Person | Seat |
|---|---|
| Elizabeth Jaffee | Deputy Director · Since at least Mar 18, 2025 |
| Francesca Barone | Chief Scientific Officer · Since at least Feb 3, 2022 |
| Henry Brem | Director, Department of Neurosurgery · Since at least Nov 17, 2025 |
| James P. Allison | Chief of the Department of Immunology · Since at least Nov 17, 2025 |
| Joseph Papa | Chairman · Since at least Nov 4, 2026 |
| Maria Ostrovsky | General Counsel · Since at least Oct 22, 2026 |
| Mark Sims | Chief Commercial Officer · Since at least Jul 6, 2026 |
| Martine Zimmermann | Director · Since at least Sep 10, 2026 |
| Paul Peter Tak | President & Chief Executive Officer · Since at least Sep 10, 2026 |
| Philip Kantoff | Co-Founder, Convergent Therapeutics · Since at least Nov 17, 2025 |
| Roy Herbst | Director, Dartmouth Cancer Center · Since at least Jul 1, 2026 |
| Seshu Tyagarajan | Chief Technology Officer · Since at least Nov 17, 2025 |
| Susan Stewart | Chief Regulatory Officer · Since at least Nov 5, 2026 |
| Theodore Jenkins | Vice President · Since at least Jul 9, 2026 |
| Udi Meirav | Director · Jul 26, 2021 – Jul 26, 2021 · Past |
Log in to ask 6ix AI your own questions about Candel Therapeutics, Inc.